ImmunoGen names board chairman Nov 12, 2009
McCluski has served on the ImmunoGen board since April 2007. He was the senior vice president and chief financial officer of Bausch & Lomb Inc. before his retirement in 2007, ImmunoGen said. (Boston Globe)
Visa's New Goal Oct 10, 2009
Oracle's Sales Miss After hours: Oracle, eBay, and Clarcor shares fall; Amgen and Immunogen strike deal. Health Care In Focus The Finance Committee's $856 billion 10-year remodeling plan for the U.S. system is released. (Forbes -- Business)
New hope in fight against AIDS Sep 19, 2009
They must find a harmless piece of the HIV virus, known as an immunogen, which will not cause infection but will stimulate the human body to produce one of these two antibodies. This would then be used as the basis for the vaccine. (The Star Online, Malaysia -- News)
ImmunoGen, Amgen in licensing deal Sep 17, 2009
ImmunoGen said Amgen has exclusive rights to the company s maytansinoid targeted antibody payload technology to develop anticancer treatments to an undisclosed target found on solid tumors. Under the deal, Waltham-based ImmunoGen receives a $1 million license payment upfront and is entitled to receive milestone payments potentially totaling $34 million plus royalties on the sales of any resulting products. (Boston Globe)
Sanaria Inc. Receives Multi-Year U.S. NIH Phase II Small Business Innovation Research Grant to Enhance Efficiency and Scale-up of its Malaria Vaccine Manufacturing Process Sep 16, 2009
For the first time, an immunogen conferring high levels of protection against malaria has been formulated as a stable, injectable vaccine candidate that meets regulatory standards. About Sanaria Inc.. (PR Newswire)
After Medarex buy, biotech investors ask who's next Jul 24, 2009
Shares of ImmunoGen (IMGN.O), another monoclonal antibody specialist, were up 3. 9 percent. (Yahoo News -- Pharmaceutical Industry News)
BMY to buy Medarex for $2.4 bn Jul 23, 2009
Other companies that specialize in monoclonal antibodies include Regeneron Pharmaceuticals Inc, Seattle Genetics (SGEN.O), which has multiple collaborations, and Immunogen Inc.. Bristol-Myers said its purchase of Medarex has been unanimously approved by the boards of both companies and is expected to close in late August. (India Times)
Vical Advances H1N1 Pandemic Influenza (Swine Flu) Vaccine May 21, 2009
SAN DIEGO, May 21, 2009 (GLOBE NEWSWIRE) -- Vical Incorporated (NasdaqGM: - ) announced today that in the two weeks since launching its program to develop a vaccine against H1N1 influenza (swine flu), the company has completed development of a prototype H1 vaccine, produced an initial supply of research-grade material, and initiated immunogenicity testing in animals ... Potential applications of the company's DNA delivery technology include DNA vaccines for infectious diseases or cancer, in... (Primezone Releases)
Alkermes signs lease to relocate HQ Apr 30, 2009
Alkermes is the latest in a string of Cambridge biotech companies including Shire, and ImmunoGen Inc. that have decided to leave East Cambridge for cheaper suburban locales. The Waltham building was completed last May and is located in the Reservoir Woods campus. (Boston Business Journal, MA)
Vical Updates Lead Vaccine Programs At NFID Vaccine Research Conference and Addresses Potential Response to H1N1 Swine Influenza Outbreak Apr 28, 2009
Phase 1 Safety and Immunogenicity Results of Vaxfectin(r)-formulated Plasmid DNA Vaccines Encoding Influenza Virus H5 Hemaggluntinin,'' an oral presentation, summarizes results from the company's successful Phase 1 trial and future goals for its pandemic influenza DNA vaccine program ... The trial was designed to assess safety and immunogenicity following vaccination, and to evaluate monovalent and trivalent Vaxfectin(r)-formulated H5N1 pandemic influenza DNA vaccines at various doses ... The... (Primezone Releases)
Vical's Vaxfectin(r) Adjuvant Named One of 100 Great Investigational Drugs in Eighth Annual Ranking by Editors of R&D Directions Apr 9, 2009
We believe that the recognition by R&D Directions of Vaxfectin(r)'s promising Phase 1 tolerability and immunogenicity results with our pandemic influenza vaccine should be helpful in our ongoing discussions with potential development partners ... Potential applications of the company's DNA delivery technology include DNA vaccines for infectious diseases or cancer, in which the expressed protein is an immunogen; cancer immunotherapeutics, in which the expressed protein is an immune system... (Primezone Releases)
Anti-idiotypic antibodies: a new approach in prion research Mar 20, 2009
From the competition seen between polyclonal and monoclonal anti-idiotypic antibodies and the original immunogen, the P1 peptide, and even more importantly, the ultimate target antigen, PrPSc, we conclude that selected antibodies bind to the antigen-combining site of the V5B2 monoclonal antibody and might even resemble the PrPSc-specific epitope. The involvement of both antigen-combining sites in the interaction between V5B2 and the most promising monoclonal anti-idiotypic antibody was further... (BioMed Central)
ThromboGenics and BioInvent Start Phase II Trial of TB-402, a Novel, Long Acting Anticoagulant for Deep Vein Thrombosis (DVT) Prophylaxis Feb 23, 2009
The scope and strength of this platform is also utilised by partners, such as ALK-Abello, Bayer HealthCare, ImmunoGen, OrbusNeich, Sanofi-Aventis, UCB and XOMA. More information is available at. (1) "The Surgeon General's Call to Action to Prevent Deep Vein Thrombosis and Pulmonary Embolism," September 15, 2008, p.1. (PR Newswire)
Vical Presents Pandemic Influenza Vaccine Results and Outlook At WHO Meeting Feb 13, 2009
The trial was designed to assess safety and immunogenicity following vaccination, and to evaluate monovalent and trivalent Vaxfectin(r)-formulated H5N1 pandemic influenza DNA vaccines at various doses ... The company's near-term goals are to confirm vaccine safety and immunogenicity in a larger number of subjects, optimize vaccine dose and adjuvant ratio, explore prime-boost regimens with different vaccines, and leverage the Phase 1 proof of concept for its DNA vaccine platform and Vaxfectin(r)... (Primezone Releases)
Vical Announces News Release and Conference Call Schedule for 2008 Financial Results Feb 10, 2009
Potential applications of the company's DNA delivery technology include DNA vaccines for infectious diseases or cancer, in which the expressed protein is an immunogen; cancer immunotherapeutics, in which the expressed protein is an immune system stimulant; and cardiovascular therapies, in which the expressed protein is an angiogenic growth factor. The company is developing certain infectious disease vaccines and cancer therapeutics internally. (Primezone Releases)
